US 12156903
Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
granted A61KA61K38/4886A61P
Quick answer
US patent 12156903 (Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome) held by Takeda Pharmaceutical Company Limited expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K38/4886, A61P, A61P11/00, A61P25/04